Human Papilloma Virus (HPV) Vaccines
Human papilloma virus (HPV) vaccines
- Pregnancy Category B
Formulations
- Intralesional, intramuscular
- Quadrivalent vaccine: HPV 6, 11, 16, 18 strains
- 9-Valent vaccine: HPV 6, 11, 16, 18, 31, 33, 45, 52, 58 strains
- Reports of IL-injection in immunocompromised and immunocompetent patients with recalcitrant verruca
- Vaccine induces cross-protective effects against various human papilloma virus (HPV) strains
- Also, prevents cancer associated with HPV strains in the vaccine (cervical, anogenital)
FDA
- Men and women aged 9-26 years; also, for those >27 years of age and at risk of HPV infection, including MSM (Health Canada)
Off label
- Verruca Vulgaris; resistant to treatment
* For further reading refer to a pharmacology source
* For further reading refer to a pharmacology source
- More effective in children than in adolescents/adults due to MHC class I of human papilloma virus (HPV)–infected cells disappear after puberty, leading to decrease in vaccine-induced HPV-specific T-cell (cytotoxic) immune response